Photobiomodulation limits oral ulcer development by regulating the immune response Authors: Siying Zhu, Jingfei Fu, Xiaoyan Li, Juan Du, Yi Liu Published: 2025 ABSTRACT AbstractBackgroundOral ulcer (OU) is among the most common oral mucosal disease, and immune factors are generally considered to play crucial roles in OU. Photobiomodulation (PBM) therapy can promote healing and alleviate pain; however, the effect and mechanism of early ulceration remain unclear.ObjectiveThis study aimed to establish a model of early persistent aggravation, assess the impact of PBM on early persistent aggravation, and map the involvement of different immune cells.MethodsIn this study, an OU model was established in C57BL/6 mice, and the mice were subsequently treated with PBM. Haematoxylin and eosin staining, stem cell immunofluorescence, and collagen III immunohistochemical staining were used to evaluate the wound healing process. Flow cytometry and immunohistochemistry were used to assess changes in various immune cells, including neutrophils, macrophages, T cells, and B cells.ResultsPBM effectively inhibited the aggravation of early ulcers and inflammation by decreasing the number of neutrophils and Th1 cells while promoting the polarization of macrophages towards the M2 phenotype and the generation of regulatory T cells (Tregs).ConclusionOur study investigated the PBM-induced patterns of changes in various immune cells during the development of OU, thereby facilitating understanding of the disease and providing a theoretical basis for the clinical application of PBM.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-025-07363-7.Keywords: Oral ulcer, Photobiomodulation therapy, T lymphocytes, Macrophages, Neutrophils, Wound healing Introduction Oral ulcers (OU) are among the most common mucosal diseases, with a prevalence of 5% to 25% [1–3], and affect eating, speaking, and overall quality of life [4]. OU presents as a well-circumscribed round ulcer with a yellow‒grey pseudomembranous centre and a well-defined red border [5]. The aetiology and pathogenesis of OU remain unclear. Potential triggering factors include immune dysregulation, genetic predisposition, and local trauma, with immune dysregulation considered to be the most important [6]. Research has indicated that OU may be mediated by various immune cells. Pathogenic factors can trigger a cascade of cytokines, chemokines and other proteins to signal immune cells, thereby causing changes in the immune microenvironment of the body [7]. On the one hand, innate immune cells maintain tissue damage and amplify inflammatory responses by releasing proinflammatory cytokines and chemokines. On the other hand, dysregulation of proinflammatory and anti-inflammatory cytokines secreted by adaptive immune cells leads to persistent inflammation and delayed wound healing. Therefore, clarifying the changes in immune cells is crucial for understanding the pathogenesis, progression and treatment of OU. OU is treated mainly by local and systemic methods [8], but the curative effect remains unsatisfactory [9], and some drugs may produce certain side effects. For example, long-term use of glucocorticoids can lead to oral mucosal atrophy and immunosuppression [10]. In recent years, photobiomodulation therapy (PBM), which is also called low-level laser therapy, has gradually emerged as a promising treatment in different fields because of its gentle and noninvasive nature [11]. PBM refers to the use of a single-wavelength coherent laser to regulate major biological processes through photophysical and photochemical effects on cells and tissues to produce a variety of beneficial physiological and clinical effects [12, 13]. The anti-inflammatory effect of PBM has led to its application in the treatment and adjuvant treatment of immune-related diseases, such as skin diseases [14], arthritis [15, 16], and allergic asthma [17]. The immunomodulatory effects of PBM have been extensively examined. Moreover, PBM has been widely used in clinical practice as an adjuvant therapy, but its specific mechanism of action is still unclear, especially since there are few reports examining the regulatory effect of PBM on immune cells in OU. Previous studies have focused on the use of PBM intervention after the formation of OU, but whether PBM can inhibit the aggravation of ulcers in the early stage of ulcer formation and its effects on changes in the oral immune environment remain unclear. To address these issues, we improved the original mouse OU model [18] by increasing the intervention time to the first day of modelling to mimic the early ulcer precursor and exacerbation stages. We also explored the roles of various immune cells, including initial and adaptive immune cells to elucidate the immune landscape during ulcer progression and intervention. Moreover, we evaluated the effect of PBM through a model of gradually worsening ulcers in vivo. This study aimed to explore the role of PBM in the early ulcer precursor and exacerbation stages by measuring mesenchymal stem cells (MSCs), collagen, and various immune cells and to verify the clinical value of PBM, providing evidence for the treatment of OU and the application of PBM. Materials and methods Animals Male C57BL/6 mice aged 7–8 weeks were used. These mice were obtained from Beijing Specific pathogen-free (SPF) Biotechnology Co., Ltd., China. The experimental animals were housed in the Experimental Animal Center of Beijing Stomatological Hospital, Capital Medical University, under SPF conditions. They were acclimatized to the housing conditions for one week before the experiments commenced. All animal experiments were conducted in accordance with the guidelines approved by the Animal Ethics Committee of Capital Medical University (Approval No. KQYY-202109-004), Beijing, China, and complied with the ARRIVE guidelines. OU model All animals were randomly divided into three groups: the PBM group, OU group and control group, with 6 mice in each group. Circular filter paper discs with a diameter of 0.2 mm were prepared using a puncher and soaked in 50% acetic acid solution. The mice were anaesthetized by the intraperitoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg). The prepared filter paper discs were placed on the tongues of the mice in the OU group and the PBM group. One minute later, the filter paper was removed. The PBM group was then irradiated with a 980 nm semiconductor laser (model Ilaser II, SensAble Technology Co., Ltd., China) at a power of 0.2 W and a density of 30 J/cm² for 60 s. The control group was maintained under identical conditions without any experimental manipulation. The Day 1 and Day 3 samples corresponded to the mice sacrificed at 24 and 72 h postmodelling, respectively. We monitored the size of the ulcers and the changes in the body weights of the mice throughout the experiment. Quantitative real-time PCR (RT‒PCR) analysis Total RNA was isolated from tongue tissues via TRIzol Reagent (Invitrogen, CA, USA). The RNA pellets were air-dried and dissolved in RNase-free water. Genomic DNA contamination was eliminated using DNase I (Takara, Beijing) at 37 °C for 5 min. First-strand cDNA was synthesized from 1 µg of total RNA using PrimeScript™ RT Master Mix (Takara, Japan) with oligo(dT) primers in a 20 µl reaction volume: 37 °C for 15 min followed by 85 °C for 5 s inactivation. Quantitative PCR was performed with the SYBR Premix Ex Taq™ kit and a CFX96 detection system (Bio-Rad Laboratories, California) with primers specific for Interleukin-6 (IL-6), Tumor necrosis factor-α (TNF-α), Interleukin-1 β (IL-1β), and GAPDH (Table S1 in the Supporting Information). Enzyme-linked immunosorbent assay (ELISA) Tongue tissues were homogenized in ice-cold RIPA buffer (Beyotime, China) supplemented with 1 mM PMSF protease inhibitor using a TissueLyser (SCIENTZ, 5 × 60 s at 25 Hz). The homogenates were subsequently centrifuged at 12,000 ×g for 20 min at 4 °C. The supernatants were collected, and the protein concentrations were determined by a BCA assay (Pierce™). For cytokine analysis, 10 µg of total protein per sample was loaded in duplicate into precoated 96-well plates using the appropriate ELISA kits according to the manufacturers’ protocols. After incubation with biotinylated detection antibodies (2 h, RT), the plates were washed 5 times with PBS-T (0.05% Tween-20). Streptavidin-HRP conjugates were added (30 min, RT), followed by TMB substrate development (15 min in the dark). The reactions were terminated with 2 N H₂SO₄. The absorbance was measured at 450 nm with a reference at 570 nm on a SpectraMax i3x microplate reader (Molecular Devices). Cell isolation from tongue tissues To isolate mononuclear cells, the tongue tissues were cut into small fragments and subjected to digestion using RPMI containing 2 mg/mL Liberase™ (Roche, Saint Louis) and 0.5 mg/mL DNase I (Sigma, Saint Louis) in a beaker with the rotor set at 37 °C for 20 min. The cell suspension was then passed through a 70-µm cell strainer consecutively to remove impurities for flow cytometry (FCM) analysis. FCM analysis The numbers of neutrophils and macrophages, M1 and M2 macrophages, total T cells, CD4 + T cells, Th1 cells, Treg cells and B cells were detected by flow cytometry. Single-cell suspensions of lymph node and tongue tissues were prepared as before. Intracellular cytokines were evaluated by stimulating the cells with a cell activation cocktail (BioLegend, California) at 37 °C for 4‒6 h. The viability of the cells was assessed by staining with the fixable viability dye zombie yellow (BioLegend, California). The cell surface markers were subsequently labelled by incubating the cells with the antibody mixture for 30 min at 4 °C in the dark. Intracellular cytokines and transcription factors were subsequently fixed with fixation/permeabilization buffer solution and stained with antibodies. A BD FACSCanto II flow cytometer (BD Biosciences, USA) was used for detection. The antibodies used for FCM analysis are shown in Supplemental Table S2. Haematoxylin and eosin (HE) The tongues were soaked in 10% neutral buffered formalin to prevent spoilage. Then, the tissues were blocked with paraffin, and the Sect. (4 μm thick) were cut, mounted onto slides, and stained with HE for pathological diagnosis and tissue damage extent analysis according to the manufacturer’s protocol. The slides were observed under a microscope (Olympus, Tokyo, Japan). Immunofluorescence (IF) Formalin-fixed paraffin-embedded tongue tissue blocks were sectioned at a thickness of 4 μm onto positively charged slides (Thermo Fisher). After being dried overnight at 37 °C, the slides were deparaffinized in xylene (3 × 5 min) and rehydrated through a graded ethanol series (100%, 95%, 80%; 2 min each). Antigen retrieval was performed by boiling in citrate buffer (pH 6.0, 95 °C) for 20 min followed by 30 min of cooling. The sections were blocked with 5% normal goat serum (Vector Laboratories) in PBS containing 0.3% Triton X-100 for 1 h at room temperature. The sections were incubated with a primary rabbit anti-CD73 antibody (Abcam #ab108982, 1:200) overnight at 4 °C. After being washed with PBS (3 × 5 min), the sections were incubated with a goat anti-rabbit IgG-Alexa Fluor 488 conjugate (Invitrogen #A-11008, 1:500) for 1 h at RT in the dark. Nuclear counterstaining was performed with DAPI (Thermo Fisher, 1 µg/mL) for 10 min. Sections were mounted using ProLong Diamond Antifade Mountant (Thermo Fisher) with #1.5 coverslips. For negative controls, the primary antibody was replaced with species-matched IgG. The staining results were observed and recorded using fluorescence microscopy or confocal microscopy. Immunohistochemistry (IHC) Formalin-fixed paraffin-embedded tissues were sectioned at a thickness of 4 μm onto charged slides (Superfrost Plus, Thermo). After deparaffinization in xylene (3 × 5 min) and rehydration through graded alcohol solutions (100%−80%), antigen retrieval was performed in citrate buffer (pH 6.0) using a microwave (95 °C, 20 min). Endogenous peroxidase activity was quenched with 3% H₂O₂ in methanol for 30 min at RT. The sections were blocked with 3% bovine serum albumin (BSA) in PBS for 1 h at 37 °C and then incubated overnight at 4 °C with anti-iNOS, anti-CD206, anti-Ly6g and anti-Collagen III antibodies (Cell Signaling Technology, Boston, MA, USA). After the samples were washed with PBS (3 × 5 min), a biotinylated secondary antibody was added, and the samples were incubated at room temperature for 1 h. Finally, the horseradish peroxidase complex and diaminobenzidine substrate were applied to visualize the staining. Statistical analysis GraphPad Prism 9.3 was used for data analysis, and each experiment was conducted at least three times independently. All data points are expressed as the mean ± standard deviation (SD). Two groups of measurement data were compared by independent sample t tests, and multiple groups of measurement data were compared by single factor analysis with a post hoc Bonferroni correction* P < 0.05; ** P < 0.01*** P < 0.001, ns = no significant difference. Randomization, blinding, and bias reduction Animal randomization was performed after the successful induction of OU. Mice were randomly assigned to either the PBM treatment group or the non-irradiated control group using a computer-generated random number sequence (GraphPad QuickCalcs). The allocation sequence was concealed from the researchers involved in the subsequent outcome assessments until all data analyses were completed. To minimize the risk of performance and detection bias, blinding procedures were implemented as follows: The researcher responsible for the daily PBM administration was not involved in any outcome measurements and evaluations. The ulcer size measurements were conducted by two independent investigators who were blinded to the group allocations. The average measurements from both investigators were used for statistical analysis. All histological assessments, including evaluation of HE-stained sections, IHC, and flow cytometry data, were performed by Research team members who were blinded to the experimental conditions. Due to the nature of the PBM treatment, it was not feasible to blind the individual administering the daily irradiation. However, all critical quantitative and qualitative outcome assessments were performed by blinded and independent personnel to ensure objective and unbiased results. Results PBM inhibits the progression of OU in mouse models To study the effect of PBM on the continuous aggravation of an OU model, we dipped filter paper in 50% acetic acid and placed it on the tongue surface of C57BL/6 mice for 1 min each day. The PBM group was irradiated with an energy density of 30 J/cm2 for 1 min. The area of the OU and the weight of the mice were recorded for 4 consecutive days. Over time, the ulcer area of the two groups continued to increase, suggesting that the model was successfully established (Fig. 1A, supplementary Fig. 1). Although the ulcer area of the PBM therapy group also continued to increase, it was significantly smaller than that of the OU group (Fig. 1B). In terms of body weight, the body weight of the OU group continued to decrease, while the weight loss of the PBM therapy group was dramatically lower than that of the OU group (Fig. 1C). HE staining revealed that the oral mucosal epithelium in the normal group of mice was intact without substantial inflammatory cell infiltration or other pathological changes. Over time, the destruction of the mucosal epithelial structure became increasingly obvious, the surface fibres were exuded, and the cells experienced vacuolar degeneration, accompanied by a large amount of inflammatory cell infiltration. Destruction of the epithelium and infiltration of inflammatory cells were also observed in the PBM group, but the degree of destruction was lower than that in the OU group (Fig. 1D). MSCs and the extracellular matrix (ECM) play important roles in wound healing. In this study, after IF of MSCs, we found that the OU group and PBM group both had lower percentages than the control group did, but the percentage in the PBM group was always greater than that in the OU group on the first and third days (Fig. 2A). IHC staining of collagen III revealed the same results (Fig. 2B). These findings demonstrate that PBM can increase MSC proliferation and the expression of collagen III, which could help accelerate ulcer healing. A Observation of tongue ulcers in mice. B Comparison of the ulcer area on the third day. C Comparison of mouse body weights over time. D HE staining of mouse tongue ulcers. Scale bar: 400 μm, 100 μm. The data are reported as the means ± SD (n = 3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 A Comparative analysis of MSC in IF results on the third day. Scale bar: 100 μm B Comparative analysis of Collagen III in IHC results on the first and third days. Scale bar: 700 μm, 100 μm, 50 μm. Data are reported as means ± SD (n = 3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 PBM inhibits neutrophils in the OU model and reduces the inflammatory response As one of the first immune cells involved in the early stage of the process of OU, the abnormal persistence of neutrophils can further prolong the process of wound healing [19]. Therefore, the number of neutrophils is crucial for the healing of OU. Through flow cytometry, we found that over time, the number of neutrophils increased in both groups, which was correlated with the worsening of the OU model. On the first day, the number of neutrophils in the PBM group was significantly lower than that in the OU group, whereas on the third day, there was no significant difference between the two groups (Fig. 3A, supplementary Fig. 2). IHC also revealed the same results (Fig. 3B). The levels of IL-6, IL-1β and TNF-α in tongue tissue on the third day of the OU model were detected by PCR and ELISA. The results showed that PBM treatment significantly decreased the expression and concentration of these cytokines in tongue tissue (Fig. 3C), suggesting that the inhibitory effect of PBM on neutrophils was more significant in the early stage. With the aggravation of ulcers, the inhibitory effect of PBM on neutrophils decreased but still exhibited potent anti-inflammatory effects. A Comparative analysis of the neutrophil flow cytometry results on the first and third days. B IHC of neutrophils on the first and third days. Scale bar: 50 μm, 20 μm. C Results of a comparative analysis of the neutrophil results on the first and third days. D Comparative analysis of the IL-6, IL-1β, and TNF-α PCR results on the third day. E Comparative analysis of the IL-6, IL-1β, and TNF-α ELISA results on the third day. The data are reported as the means ± SD (n = 3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 PBM regulates macrophages in the OU model Macrophages have been identified as key players in the progression of tissue inflammation. Flow cytometry analysis revealed that on day 1, the macrophage ratio in both the OU and PBM groups was higher than that in the control group, with the PBM group showing a significantly greater increase compared to the OU group. By day 3, the PBM group maintained a higher macrophage ratio relative to the control, whereas no significant difference was observed between the OU and control groups (Fig. 4A). On day 1, the proportion of M1 macrophages in the PBM group was lower than that in the OU group; however, by day 3, no significant difference was detected between the two groups. In contrast, the proportion of M2 macrophages in the PBM group remained elevated compared to the OU group at both day 1 and day 3, indicating that PBM promotes M2 macrophage polarization and contributes to ulcer healing (Fig. 4B, C). These findings suggest that PBM can increase the overall macrophage population, reducing the ratio of M1 macrophages and enhancing the ratio of M2 macrophages, thereby decreasing inflammation and facilitating wound healing. A Comparison of the flow cytometry results for macrophages on the first and third days. B Comparison of the flow cytometry results for M1 and M2 macrophages on the first and third days. The data are reported as the means ± SD (n = 3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 PBM regulates T cells in the OU model The balance of CD4+ T-cell subsets has been reported to play an important role in the pathogenesis of OU. Th1 cells promote disease progression, whereas Treg cells facilitate tissue remodelling and regeneration. The results revealed that, on the first day, there were no differences in the number of CD4+ T cells among the groups; however, on the third day, the number of T cells in the PBM group was lower than that in the OU group (Fig. 5A). On the same day, the ratio of Th1 cells in the OU group increased, whereas that in the PBM group decreased significantly and was even significantly lower than that in the control group (Fig. 5B). For Treg cells, there was no difference between the PBM and OU groups on the first day, and on the third day, the percentage in the PBM group was significantly greater than that in the OU group, while that in the OU group was even lower than that in the control group (Fig. 5C). These results indicate that the immune response time occurred late during the development of ulcers, Th1 cell expression increased when ulcers occurred, and Treg numbers decreased at the same time. Therefore, PBM can effectively suppress the Th1 immune response while promoting Treg cells, thereby inhibiting inflammation and accelerating the healing process. A Comparison of flow cytometry results for CD4 + T cells on the first and third days. B Comparison of flow cytometry results for IFN-γ + CD4 + T cells on the first and third days. C Comparison of flow cytometry results for Treg + CD4 + cells on the first and third days. D Comparison of B-cell flow cytometry results on the first and third days. The data are reported as the means ± SD (n = 3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 In addition, we detected the ratio of B cells on the first day, but there were no differences between the OU group and the PBM group or between the OU group and the control group. We also detected the ratio of B cells on the third day, and there were no differences between the OU group and the PBM group or between the OU group and the control group (Fig. 5D). Discussion Previous studies have confirmed that PBM treatment is beneficial for conventional OU [20], and clinical trials have indicated that PBM treatment not only aids in the healing of common OU but also alleviates pain [21]. Many studies have shown that PBM can promote the healing of OU after its formation, but in clinical practice, many patients suffer from a prodromal stage of OU before overt ulceration [22]. If PBM could be used at such an early stage, it would effectively reduce the duration and degree of pain for patients. Therefore, to explore this clinical problem, we developed a murine OU model in which ulceration was induced by a 1-minute topical application of 50% acetic acid-soaked filter paper to the tongue. PBM (980 nm semiconductor laser at a power of 0.2 W and a density of 30 J/cm² for 60 s) [23]was initiated just after removing the paper—corresponding to the prodromal phase (clinical preulcerative stage)—and continued for 3 days, representing the early ulcerative phase characterized by progressive worsening, which is very different from other models. This design mirrors the clinical timeline in which patients experience prodromal symptoms (e.g., burning, erythema) before overt ulcer formation and subsequent inflammatory escalation. Our research demonstrated that PBM remains effective in the early stages of ulcer formation. For example, during daily exposure to 50% acetic acid, PBM was able to hinder the progression of OU and reduce redness and swelling on the first and third days. This finding suggests that PBM therapy may serve not only as a treatment for OU but also as a supportive measure for preventing the aggravation of ulcers. In addition, we also found that PBM can effectively mitigate early-stage ulcer inflammation and disease progression through immunomodulatory mechanisms. Specifically, PBM reduced neutrophil infiltration on Day 1, but this difference was not significant by Day 3. The levels of inflammatory cytokines (IL-6, IL-1β, and TNF-α) were lower in PBM-treated tissue. These findings suggest that the anti-inflammatory effects of PBM may be most pronounced in the early stages. Compared with OU, PBM favoured an increase in M2 macrophages, supporting a shift towards a reparative immune environment. However, M1 macrophage levels were also transiently elevated in PBM-treated mice early on, indicating a complex temporal modulation. For T cells, on Day 3, Th1 cells were suppressed, whereas Tregs were elevated in PBM-treated mice. The CD4+ T cell population as a whole showed minimal changes. These observations are consistent with a shift towards anti-inflammatory T-cell profiles. No significant changes were observed in B-cell frequency, which is consistent with the literature suggesting a limited role for B cells in ulcer pathogenesis. Pathological examinations of ulcerated areas have revealed significant white blood cell infiltration, with the extent of infiltration varying with disease progression and severity [7]. Neutrophils play a dual role in wound healing; insufficient numbers can lead to infections and delayed healing, whereas excessive numbers can cause tissue damage and delay healing [24]. Although T-cell-mediated immune dysfunction is a primary cause of OU, damage to the mucosal epithelium by neutrophils is also important to consider [25]. Thus, neutrophils are crucial immune cells to monitor during both the worsening and healing stages of OU. In our study, we observed that daily application of 50% acetic acid to mouse tongues led to an increase in the ulcer area and redness over time. Analysis of neutrophils through flow cytometry and IHC revealed that their numbers increased as the ulcers worsened. Notably, on the first day, the PBM group had significantly fewer neutrophils than the OU group did, but by the third day, there was no significant difference between the two groups, although the PBM group still presented lower levels of inflammatory factors. The evidence implicating neutrophils in RAS pathogenesis is both limited and conflicting; thus, their specific role remains unclear [26]. Studies have suggested that oral microorganisms may play an important role in the occurrence and development of OU. In active OU lesions, the composition of bacteria and fungi colonizing the healthy oral mucosa undergoes changes, which can persist to some extent even after the ulcer has healed [27]. Based on the observed data, we hypothesize that the sustained elevation in neutrophil counts in the PBM group on day 3 may be linked to bacterial invasion, counteracting the immunomodulatory effects of PBM. While blue light spectra are well-documented for their antibacterial efficacy [28], the near-infrared spectrum employed here primarily influences immune responses without confirmed antibacterial activity. Thus, a possible hypothesis is that bacterial proliferation could stimulate neutrophil recruitment, potentially masking any suppressive effects of PBM on these cells. Future studies should explicitly test this hypothesis by assessing bacterial loads and evaluating combined PBM-antimicrobial strategies to clarify interactions between infection and therapy. Macrophages, another type of immune cell, are vital for inflammation and repair [29], and their quantity, typeand ratio are very important [30]. The classification of macrophages is primarily based on their polarization states, including the unpolarized state (M0), M1, and M2, among which the M2 phenotype can be further subdivided into subtypes such as M2a and M2c [31–33]. Different macrophage phenotypes play distinct roles in the inflammatory response and tissue remodelling. The transition of the macrophage phenotype from the proinflammatory M1 phenotype to the healing M2 phenotype has emerged as a crucial process in promoting wound healing [34]. This study mainly focused on the classical M1 and M2 as a basis to preliminarily investigate the effect of PBM on macrophages. On the first day, PBM promoted the proportion of total macrophages while reducing the M1 ratio and increasing the M2 ratio. By the third day, although no significant differences were observed in M1 or total macrophage levels, the M2 proportion still differed compared to the OU group. These findings suggest that the effect of PBM on M1 polarization may occur at the earliest stage, while PBM consistently promotes M2 polarization, thereby contributing to inflammation suppression and enhanced healing. Recent studies have shown that M2 macrophages can be induced to appear early in wound healing, particularly under external interventions. For example, in exercise intervention experiments, exercise significantly suppressed M1 macrophage infiltration and increased M2 macrophage numbers from the early stages of wound healing, indicating that the M2 phenotype may be activated prematurely during the early phase, thereby accelerating healing [35]. Another study revealed that B cells recruited to the wound site in the early stages promote M2 macrophage polarization, further supporting the notion that the M2 phenotype can play a role during the inflammatory phase, rather than being limited to later stages [36]. Additionally, in chronic wounds, the imbalance between M1 and M2 macrophages has been emphasized as a hindrance to healing. However, interventions such as biomaterial-based or immunomodulatory strategies can promote the early emergence of the M2 phenotype, thereby shortening the inflammatory phase [37, 38]. Moreover, studies have highlighted the overlap and plasticity of macrophage phenotypes, suggesting that M1 and M2 macrophages are not strictly binary but exist along a continuous spectrum, where they may coexist or alternate in the wound microenvironment [39]. The early increase in M2 macrophages observed in this study following PBM intervention is consistent with these findings. T cells, particularly Th1 cells, are also involved in OU and secrete inflammatory factors that exacerbate this condition. Immune imbalance is considered one of the causes of OU. For example, the decrease in the CD4/CD8 ratio may be related to the pathogenesis of OU. An increase in the Th1/Th2 ratio may delay wound healing [40]. Treg cells are recognized for their effectiveness in managing inflammation in the oral mucosa. Research has indicated that the elimination of Treg cells results in the infiltration of effector T cells linked to oral mucosal inflammation [41]. A lack of Treg cells leads to severe oral mucosal inflammation, while the transfer of Treg cells can help alleviate this condition, demonstrating that Treg cells play a significant role in oral mucosal inflammation, such as OU [42]. Our study confirmed that PBM can reduce Th1 cells and increase Treg cells, thereby controlling inflammation and promoting ulcer healing, which is consistent with other findings [43]. Owing to some controversy about the effects of B cells on ulcers, we also tested B cells. Most studies suggest that B cells do not play a significant role in the onset and progression of OU. However, a few investigations have reported an increase in the number of B cells during the occurrence of OU [7], and B cells may act as regulators of tissue regeneration [44, 45]. B cells showed no significant changes in our study, which aligns with the majority of the research findings. Studies have found that under inflammatory or oxidative stress conditions, PBM can significantly reduce reactive oxygen species (ROS) levels [46–48]. ROS not only acts as an inflammatory mediator to promote tissue damage but also regulates the functions of various immune cells [47]. For example, in a periodontitis mouse model, PBM application reduced ROS in gingival cells, decreased systemic inflammation, and modulated cytokine balance, such as reducing IL-6 and increasing IL-10, which demonstrates that PBM regulates oxidative stress and inflammatory responses through ROS [46]. ROS can regulate immune cell functions, such as in macrophages, where ROS levels influence the activation of the M1 phenotype, thereby exacerbating inflammatory responses [47]. Therefore, we similarly speculate that PBM modulates the immune microenvironment under OU by generating ROS. Of course, some studies have reported that different wavelengths have specific or even opposite effects on ROS production [49, 50]. The impact of the parameters used in this study on ROS still needs further clarification to provide some theoretical basis for clinical applications. The findings of this study suggest that PBM holds considerable clinical translational potential. Based on our study, this therapy is suitable for high-risk populations prone to OU, such as oncology patients undergoing radiotherapy or chemotherapy (for preventing and managing oral mucositis) and individuals with recurrent aphthous stomatitis during the prodromal stage. As a safe and effective adjuvant to existing treatment regimens [51, 52]—including topical analgesics, anti-inflammatory agents, and oral care protocols—PBM could reduce pain caused by OU and accelerate healing [53]. Its non-invasive and analgesic nature allows for seamless integration into routine clinical practice. When applied with appropriate parameters [21], PBM demonstrates an excellent safety profile, devoid of significant thermal effects or risks of tissue damage. Extensive clinical studies have confirmed its favorable tolerability and minimal side effects [54]. This study further found that PBM remains effective in inhibiting the progression of early-stage ulcers; with further research, it may even enable at-home treatment via portable devices upon the emergence of early symptoms. Thus, our work lays a foundation for the future integration of PBM as a first-line non-pharmacological intervention in the early management of OU. While our study provides novel insights into the early therapeutic effects of PBM on OU progression, several limitations should be acknowledged to guide future research. First, the experimental timeline in this work was designed to capture the early immune dynamics; thus, detailed analyses were centered on Days 1 and 3. In parallel, we performed longitudinal observations through Day 7, which revealed that PBM could accelerate ulcer healing (supplementary Fig. 3–5), we selected 1 day and 3 days as observation points, with a focus on immune regulatory effects during the early stages of ulcers. Therefore, we did not assess later healing stages, such as epithelial remodelling. Future studies should extend the observation period to evaluate long-term healing and relapse. Second, we carried out experiments according to the parameters recommended by most of the literature and obtained significant results, but it is not clear whether there are more optimal parameters. We will continue to analyse dose‒response relationships to identify the optimal treatment parameters. Third, given the correlation between microbial imbalance and the pathogenesis of OU and the observed reduction in the inhibitory effect of PBM on neutrophils on the third day, microbial assessment is crucial for understanding the sustained presence of neutrophils in the therapeutic effects of PBM. In the future, we will perform microbiome analyses to clarify immune‒microbiota interactions. Fourth, although the model used in this study is the classic method for establishing mouse OU models, the acetic acid-induced ulcer model primarily reflects traumatic ulcers and does not fully represent the clinical conditions of OU, which are mainly aphthous ulcers. Fifth, while the current sample size in this study was sufficient to achieve statistical significance, the relatively small sample size in this study may constrain the statistical power and generalizability of the findings. Therefore, the results should be interpreted with caution, and future studies with larger sample sizes are warranted to validate these conclusions. Incorporating functional metrics such as epithelial closure, nociception, or oral intake will provide valuable data for clinical treatment and molecular discovery. Conclusion In summary, our study utilized a model of progressively worsening OU to investigate the immune-regulating capabilities of PBM. We found that PBM treatment was associated with the modulation of innate and adaptive immune responses in a murine model of OU, including a reduction in proinflammatory markers such as neutrophils, M1 macrophages, Th1 cells, and inflammatory cytokines (IL-6, IL-1β, and TNF-α) and an increase in regulatory immune phenotypes such as M2 macrophages and Tregs. These findings suggest a potential supportive role for PBM in tissue healing, which warrants further validation. Supplementary Information Supplementary Material 1. Acknowledgements Not applicable. Abbreviations Oral ulcer Photobiomodulation Regulatory T cells T helper 1 cell Mesenchymal stem cells Specific pathogen-free Quantitative Real-Time PCR Analysis Tumor necrosis factor-α Interleukin-6 Interleukin-1 beta Flow cytometry Hematoxylin and eosin Immunofluorescence staining Immunohistochemistry Extracellular matrix Enzyme-linked immunosorbent assay Control Reactive oxygen species standard deviation Authors’ contributions Yi Liu: Conceptualization, Methodology, Supervision, Project administration, Resource, Funding acquisition, Writing-Review & Editing.Siying Zhu and Jingfei Fu: Investigation, Data curation, Writing-Original draft, Validation.Xiaoyan Li: Writing-Review & Editing, Visualization.Juan Du: Methodology, Supervision, Writing-Review & Editing.Siying Zhu and Jingfei Fu contributed equally to this work. Funding This work was supported by National Key R&D of Program of China(Grant NO. 2022YFC2504200), the Innovation Research Team Project of Beijing Stomatological Hospital, Capital Medical University (CXTD202202)and Young Scientist Program Of Beijing Stomatological Hospital, Capital Medical University (NO. YSP202402). Data availability All data generated or analysed during this study are included in this published article and its supplementary data. Please contact the corresponding author for data requests. Declarations Ethics approval and consent to participate All animal experiments were conducted in accordance with the guidelines approved by the Animal Ethics Committee of Capital Medical University (Approval No. KQYY-202109-004), Beijing, China, and complied with the ARRIVE guidelines. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Siying Zhu and Jingfei Fu are contributed equally to this work. Change history 3/7/2026 The incorrect author affiliations was corrected. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data generated or analysed during this study are included in this published article and its supplementary data. Please contact the corresponding author for data requests.